Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain

Movement Disorders

Volumn 16, Issue 6, 2001, Pages 1110-1114

  Hassani, Oum Kaltoum ^a   Mouroux, Mireille ^a   Bohme, Georg Andrees ^b   Stutzmann, Jean Marie ^b   Féger, Jean ^a,c  

^a Laboratory of Neurophysics and Physiology   (France)

^b SANOFI   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Basal ganglia; Excitotoxicity; Glutamate release; Neurodegenerative diseases; Neuroprotection; Parkinson's disease; Sodium channels blockers

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); APOMORPHINE; CHLORAL HYDRATE; DESIPRAMINE; OXIDOPAMINE; PARGYLINE; RILUZOLE; SODIUM CHANNEL BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN REGION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; FEEDBACK SYSTEM; MALE; MESENCEPHALON; NERVE CELL MEMBRANE POTENTIAL; NERVE CONDUCTION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ADRENERGIC AGENTS; ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; FUNCTIONAL LATERALITY; MALE; MODELS, ANIMAL; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; RILUZOLE; SODIUM CHANNEL BLOCKERS; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

EID: 0035526261     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1219     Document Type: Article

References (35)

1. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375.
2. Bergman H, Wichmann T, Karmon B, Delong MR. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994;72:507-520.
3. Hassani O-K, Mouroux M, Féger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 1996;72:105-115.
4. Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 1993;5:382-389.
5. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, Perret JE, Benabid AL. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995;345:91-95.
6. Bergman H, Wichman T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990; 249:1436-1438.
7. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998;44:S175-S188.
8. Kitai ST, Deniau JM. Cortical inputs to the subthalamic nucleus: intracellular analysis. Brain Res 1981;214:411-415.
9. Rouzaire-Dubois B, Scarnati E. Pharmacological study of the cortical-induced excitation of subthalamic nucleus neurones in the rat: evidence for amino acids as putative neurouransmitters. Neuroscience 1987;21:429-440.
10. Mouroux M, Féger J. Evidence that the parafascicular projection to the subthalamic nucleus is glutamatergic. Neuroreport 1993;4: 613-615.
11. Mouroux M, Hassani O-K, Féger J. Electrophysiological study of the excitatory parafascicular projection to the subthalamic nucleus and evidence for ipsi- and contralateral controls. Neuroscience 1995;67:399-407.
12. Hammond C, Rouzaire-Dubois B, Féger J, Jackson A, Crossman AR. Anatomical and electrophysiological studies on the reciprocal projections between the subthalamic nucleus and the nucleus tegmenti pedonculopontinus in the rat. Neuroscience 1983;9:41-52.
13. Orieux G, Francois C, Feger J, Yelnik J, Vila M, Ruberg M, Agid Y, Hirsch EC. Metabolic activity of excitatory parfascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. Neuroscience 2000;97:79-88.
14. Bezard E, Stutzmann JM, Imbert C, Boraud T, Boireau A, Gross CE. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model. Eur J Pharmacol 1998; 356:101-104.
15. Chéramy A, Barbeito L, Godeheu G, Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 1992;147:209-212.
16. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993;250:473-476.
17. Prakriya M, Mennerick S. Selective depression of low-release probability excitatory synapses by sodium channel blockers. Neuron 2000;26:671-682.
18. Debono MW, Le Guern J, Canton T, Doble A, Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993;235:283-289.
19. Hubert JP, Delumeau JC, Glowinski J, Prémont J, Doble A. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br J Pharmacol 1994;113:261-267.
20. Benoit E, Escande D. Riluzole specifically blocks inactivated Na-channels in myelinated nerve fibre. Pflügers Arch 1991;419:603-609.
21. Doble A. Effects of riluzole on glutamatergic neurotransmission in the mammalian central nervous system, and other pharmacological effects. Rev Contemp Pharmacother 1997;8:213-225.
22. Hudson JL, van Horne CG, Stromberg I, Brock S, Clayton J, Masserano J, Hoffer BJ, Gerhardt GA. Correlation of apomorphine-induced and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 1993;626:167-174.
23. Hebert T, Drapeau P, Pradier L, Dunn RJ. Block of the rat brain IIA sodium channel subunit by the neuroprotective drug riluzole. Mol Pharmacol 1994;45:1055-1060.
24. Bohme GA, Le Guern S, Boudeau P, Randle JCR. Riluzole: frequency-dependent actions link inhibition of sodium channels and inhibition of synaptic transmission. Soc Neurosci Abstr 1994; 20:1519.
25. MacIver B, Amagasu SM, Mikulec AA, Monroe FA. Riluzole anesthesia: use-dependent block of presynaptic glutamate fibers. Anesthesiology 1996;85:626-634.
26. Boraud T, Bezard E, Stutzmann JM, Bioulac B, Gross CE. Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey. Neurosci Lett 2000;281:75-78.
27. Amalric M, Ouagazzal A, Baunez C, Nieoullon A. Functional interactions between glutamate and dopamine in the rat striatum. Neurochem Int 1994;25:123-131.
28. Hassani O-K, Féger J. Effects of local injection of dopamine receptor agonists on subthalamic neurones in normal and 6-OHDA lesioned rats: an electrophysiological and c-Fos study. Neuroscience 1999;92:533-543.
29. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, Sibley RS. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250:1429-1432.
30. Barneoud P, Mazadier M, Miquet JM, Parmentier S, Dubedat P, Doble A, Boireau A. Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience 1996;74:971-983.
31. Benazzouz A, Boraud T, Dubedat P, Boireau A, Stutzmarm JM, Gross C. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 1995;284:299-307.
32. Boireau A, Dubedat P, Bordier F, Peny C, Miquet JM, Durand G, Meunier M, Doble A. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. NeuroReport 1994;5:2657-2660.
33. Chergui K, Akaoka H, Charlety PJ, Saunier CF, Buda M, Chouvet G. Subthalamic nucleus modulates burts firing of nigral dopamine neurones via NMDA receptors. NeuroReport 1994;5:1185-1188.
34. Marey-Semper I, Gelman M, Lévi-Strauss M. A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation. J Neurosci 1995;15:5912-5918.
35. Turski L, Bressler K, Rettig KJ, Löschman PA, Watchel H. Protection of the substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991;349:414-418.